JP4436084B2 - Collagen production promoter and collagen cross-linking formation inhibitor - Google Patents
Collagen production promoter and collagen cross-linking formation inhibitor Download PDFInfo
- Publication number
- JP4436084B2 JP4436084B2 JP2003205800A JP2003205800A JP4436084B2 JP 4436084 B2 JP4436084 B2 JP 4436084B2 JP 2003205800 A JP2003205800 A JP 2003205800A JP 2003205800 A JP2003205800 A JP 2003205800A JP 4436084 B2 JP4436084 B2 JP 4436084B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- coleus
- extract
- skin
- cross
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】
【発明が属する技術分野】
本発明は、コラーゲン産生促進剤及びコラーゲン架橋形成阻害剤に関し、特に皮膚老徴のひとつであるシワの予防、改善に有効性を発揮するコラーゲン産生促進剤及びコラーゲン架橋形成阻害剤に関する。
【0002】
【従来の技術】
老化にともなう皮膚変化のひとつであるシワは、真皮結合組織の主な構成成分であるコラーゲンの減少や質的変化により皮膚弾力性の低下が起こることが原因となって発生する。シワの形成を抑制する手段として、従来からコラーゲン、ヒアルロン酸等の真皮細胞外マトリックス成分を皮膚に塗布するのが主流であった。しかし、これらは十分な効果を有するものではなかった。
【0003】
また、近年皮膚の加齢変化を予防・改善する薬物としてビタミンA誘導体が注目され、広く用いられている(特許文献1、非特許文献1)。ビタミンA誘導体の効果は極めて多岐にわたるが、その一つとして皮膚におけるコラーゲン産生促進効果が知られている。しかし、その効果は必ずしも満足の行くものでないことから、この効果を増強する手段が強く望まれていた。
【0004】
【特許文献1】
特開平08−073338
【非特許文献1】
圷信子、フレグランスジャーナル、2001、29(2)、37−42
【0005】
一方、コラーゲンの質的変化の一つに架橋形成が上げられる。コラーゲンは生体内での代謝回転が遅く、真皮結合組織中に長く存在する間にコラーゲン分子内及び分子間に架橋が起こることで、線維芽細胞の活性が低下すると共に、コラーゲンが不溶化し、結合組織本来の物性が低下して肌の弾力が低下する原因になっていた(非特許文献2,3,4)。
【0006】
【非特許文献2】
Mauron,Prog.Fd.Nutur.Sci.,5:5−35,1981
【非特許文献3】
Howard,Exp.Cell.Res.,228:132−137,1998
【非特許文献4】
Tiollier,Exp.Cell.Res.,191:95−104,1990
【0007】
そこで、コラーゲン架橋形成を阻害することにより、皮膚の老化を防止でき、しかも安全性の点でも問題のないコラーゲン架橋阻害剤が望まれていた。
【0008】
コラーゲンを酵素分解して得られるコラーゲンペプチドに線維芽細胞におけるコラーゲン生成を促進する効果があることは知られている(特許文献2)。またコリウスの抽出物には、紫外線によるビタミンAレセプターの減少を防ぎ、ビタミンA誘導体のシワ予防・改善効果を高める効果が知られている(特許文献3)。
【0009】
【特許文献2】
特開2000−309521号
【特許文献3】
特願2003−201207号
【0010】
しかしながら、コラーゲンペプチド、ビタミンA誘導体、コリウス抽出物を特定の組み合わせで組み合わせることにより、コラーゲン産生効果やコラーゲン架橋形成阻害効果を促進させることは報告されていなかった。
【0011】
【発明が解決しようとする課題】
本発明は、このような状況下為されたものであり、コラーゲン産生を促進し、コラーゲンの架橋形成を阻害する安全性の高い成分を探索し、該成分を有効成分として含有するシワの予防、改善に優れたコラーゲン産生促進剤及びコラーゲン架橋形成阻害剤を提供することを課題とする。
【0012】
【課題を解決するための手段】
この様な事情により、本発明者らは鋭意研究を重ねた結果、コラーゲンペプチドにビタミンA誘導体やコリウス抽出物を併用することで、コラーゲン産生促進効果を相乗的に増強することを見出した。また、ビタミンA誘導体、コラーゲンペプチド、コリウス抽出物にコラーゲン架橋形成阻害効果を見出し、さらにはコラーゲンペプチドにビタミンA誘導体やコリウス抽出物を併用することで、コラーゲン架橋形成阻害効果が相乗的に増強することを見出し、本発明を完成するに至った。
【0013】
すなわち、本発明は、ビタミンA誘導体、コラーゲンペプチド、コリウスの抽出物を含有することを特徴とするコラーゲン産生促進剤及びコラーゲン架橋形成阻害剤である。
【0014】
本発明に係るコラーゲンペプチドの出発原料であるコラーゲンまたはゼラチンは、牛、豚、鳥などの骨、皮、腱またはヒラメ、カレイ、鮭、鯛、鮪、鮫などの骨、皮、腱、鱗、浮き袋等を用いることが可能である。上記コラーゲンまたはゼラチンの抽出・精製は、公知の方法を用いて行うことができる。
【0015】
コラーゲンペプチドは、上記コラーゲンペプチドを、タンパク分解酵素を用いて加水分解することにより得ることができる。用いる酵素は、特に限定されるものではなく、トリプシン、キモトリプシン、ズブチリシン、エラスターゼ、プロリン特異性プロテアーゼ、ストレプトコッカス属の微生物が産生するプロテアーゼ、アスペルギルス属の微生物が産生するプロテアーゼ、ストレプトミセス属の微生物が産生するプロテアーゼ、リゾープス属の微生物が産生するプロテアーゼ、バチラス属の微生物が産生するプロテアーゼ、乳酸菌が産生するプロテアーゼ、パパイン、ブロメライン、ククミシン、ペプシン、サーモリシン等が利用できる。また、クロストリジューム属、ストレプトミセス属などの細菌、放線菌あるいは真菌由来のコラゲナーゼも利用可能である。また、遺伝子組み換え技術により他の菌体に産生させたプロテアーゼであっても良い。さらに、複数の酵素を混合して使用しても良い。
【0016】
加水分解に使用する酵素量は、原料に対して重量比0.01%〜10%程度、好ましくは0.1〜5%程度が良く、温度条件は室温〜90℃、好ましくは37℃〜55℃、反応時間は1〜24時間、好ましくは1〜8時間処理する。またpH条件は酵素添加前に最適pHに調整する。加水分解終了後、加熱して酵素を失活させ、冷却後必要に応じてろ過、脱色、脱臭、脱塩、濃縮、乾燥を行うと良い。
【0017】
本発明のコラーゲンペプチドは、酵素の種類、濃度、反応時間等、反応条件を調整することで得ることができる。コラーゲンペプチドの平均分子量は280〜3000が好ましく、平均分子量500〜1500が特に好ましい。酵素による加水分解物は、ゲルろ過クロマトグラフィー等の公知の方法を用いて特定の分子量の分画物を得ることができる。
【0018】
本発明に用いるシソ科の植物としては、シソ科ソレノステモン属、コリウス属などに属し、ソレノステモン・スクテラリオイデス(Solenostemonscutellarioides)、コリウス・ブルメイ(Coleus blumei)、コリウス・スクテラリオイデス(Coleus scutellarioides)、コリウス・ラビアタエ(Coleus labiatae)などがある。特に、ソレノステモン・スクテラリオイデス、コリウス・ブルメイは園芸品種「コリウス」として広く販売されている。中でも中国で彩葉草といわれているコリウス・スクテラリオイデスが好ましい。
【0019】
本発明に用いる特定のシソ科に属する植物抽出物とは、植物体の葉、茎、花、根等の植物体の一部又は全草から抽出したものである。好ましくは、植物体の葉、茎から抽出したものが良い。その抽出方法は特に限定されず、例えば、加熱抽出したものであっても良いし、常温抽出したものであっても良い。
【0020】
抽出する溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール(1,3−ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコール等の極性溶媒が良く、特に好ましくは、水、エタノール、1,3−ブチレングリコール及びプロピレングリコールが良い。これらの溶媒は一種でも二種以上を混合して用いても良い。
【0021】
上記抽出物は、抽出した溶液のまま用いても良く、必要に応じて、濃縮、希釈及び濾過処理、活性炭等による脱色、脱臭処理等をして用いても良い。更には、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いても良い。
【0022】
本発明で用いられるビタミンA誘導体は、酢酸レチノール、パルミチン酸レチノール、ビタミンA油等であり、市販品を用いることができる。
【0023】
本発明のコラーゲン産生促進剤及びコラーゲン架橋形成阻害剤には、上記ビタミンA誘導体、コラーゲンペプチド及びコリウスの抽出物をそのまま使用しても良く、効果を損なわない範囲内で、通常の皮膚外用剤に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、pH調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤、賦形剤、安定剤、保存剤、結合剤、崩壊剤等の成分を配合することもできる。
【0024】
本発明に用いるコラーゲン産生促進剤及びコラーゲン架橋形成阻害剤は、化粧品、医薬部外品及び医薬品のいずれにも用いることができ、その剤型としては、例えば、化粧水、クリーム、乳液、ゲル剤、エアゾール剤、軟膏、パップ剤、ペースト剤、プラスター剤、エッセンス、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、等が挙げられる。
【0025】
本発明に用いるビタミンA誘導体、コラーゲンペプチド、コリウスの抽出物の配合量は特に限定されないが、本発明のコラーゲン産生促進剤及びコラーゲン架橋形成阻害剤、皮膚外用剤全量に対し、乾燥物に換算して0.0001〜75重量%の範囲が好ましく、さらに好ましくは0.001〜30重量%である。0.0001重量%以下ではコラーゲン産生促進効果及びコラーゲン架橋形成抑制効果が低く、また75重量%を超えても効果に大きな増強はみられにくく、効率的でない。また、添加の方法については、予め加えておいても製造途中で添加しても良く、作業性を考えて適宜選択すれば良い。
【0026】
次に本発明を詳細に説明するため、実施例として本発明に用いる抽出物の製造例、処方例及び実験例を挙げるが、本発明はこれに限定されるものではない。実施例に示す配合量は重量%を示す。
【0027】
製造例1 パパイン加水分解によるコラーゲンペプチド1
コラーゲンタンパクとして、鮭皮より調製したゼラチン30gを蒸留水300mLに加温溶解した。パパイン(天野エンザイム社製)300mgを加え、アンモニア水にてpH7.0に調製した後50℃で1時間放置した。反応終了後、反応液を100℃で15分間加熱し、酵素を失活させた。次いで活性炭素処理後、凍結乾燥し平均分子量3000のコラーゲンペプチドを得た。
【0028】
製造例2 パパイン加水分解によるコラーゲンペプチド2
製造例1における活性炭素処理液を蒸留水で平衡化したBio−Gel P−2(BIO−RAD社製)によるゲル濾過クロマトグラフィーを行い、平均分子量が2000、800、280の画分を凍結乾燥した。
【0029】
製造例3 コラゲナーゼ加水分解によるコラーゲンペプチド
コラーゲンタンパクとして、鯛鱗より調製したゼラチン30gを蒸留水300mLに加温溶解した。コラゲナーゼタイプI(Worthington Biochemical Corp製)300mgを加え、アンモニア水にてpH7.5に調製した後37℃で1時間放置した。反応終了後、反応液を100℃で15分間加熱し、酵素を失活させた。次いで活性炭素処理後、凍結乾燥し平均分子量400のコラーゲンペプチドを得た。
【0030】
製造例4 パパイン及びバチラス属の微生物が産生するプロテアーゼ加水分解によるコラーゲンペプチド1
コラーゲンタンパクとして、カレイ皮より調製したゼラチン30gを蒸留水300mLに加温溶解した。パパイン(天野エンザイム社製)、バチラス属の微生物が産生するプロテアーゼ(天野エンザイム社製)を各300mg加え、アンモニア水にてpH7.5に調製した後50℃で3時間放置した。反応終了後、反応液を100℃で15分間加熱し、酵素を失活させた。次いで活性炭素処理後、凍結乾燥し平均分子量1500のコラーゲンペプチドを得た。
【0031】
製造例5 パパイン及びバチラス属の微生物が産生するプロテアーゼ加水分解によるコラーゲンペプチド2
製造例4の活性炭素処理液を蒸留水で平衡化したBio−Gel P−2(BIO−RAD社製)によるゲル濾過クロマトグラフィーを行い、平均分子量800の画分を凍結乾燥した。
【0032】
製造例6 コリウスの熱水抽出物
コリウス(Coleus scutellarioides)の全草の乾燥物20gに精製水400mLを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してコリウスの熱水抽出物を1.8g得た。
【0033】
製造例7 コリウスのエタノール抽出物
コリウス(Coleus scutellarioides)の全草の乾燥物100gにエタノール900mLを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固してコリウスのエタノール抽出物を5.9g得た。
【0034】
製造例8 コリウスの50%1,3−ブチレングリコール抽出物
コリウス(Coleus scutellarioides)の全草の乾燥物100gに精製水1kg及び1,3−ブチレングリコール1kgを加え、常温で7日間抽出した後、濾過し、コリウスの50%1,3−ブチレングリコール抽出物を1.9kg得た。
【0035】
実施例1 乳液1
[製造方法]成分2〜8を加熱溶解して混合し、70℃に保ち油相とする。成分1及び10〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分9を加え、更に30℃まで冷却して製品とする。
【0036】
実施例2 乳液2
[製造方法]成分1〜8を加熱溶解して混合し、70℃に保ち油相とする。成分10〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分9を加え、更に30℃まで冷却して製品とする。
【0037】
実施例3 乳液3
[製造方法]成分2〜8を加熱溶解して混合し、70℃に保ち油相とする。成分1及び10〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分9を加え、更に30℃まで冷却して製品とする。
【0038】
実施例4 乳液4
[製造方法]成分2〜9を加熱溶解して混合し、70℃に保ち油相とする。成分1及び11〜14を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、更に30℃まで冷却して製品とする。
【0039】
実施例5 乳液5
[製造方法]成分2〜9を加熱溶解して混合し、70℃に保ち油相とする。成分1及び11〜14を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、更に30℃まで冷却して製品とする。
【0040】
実施例6 乳液6
[製造方法]成分3〜9を加熱溶解して混合し、70℃に保ち油相とする。成分1〜2及び11〜14を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、更に30℃まで冷却して製品とする。
【0041】
実施例7 乳液7
[製造方法]成分3〜10を加熱溶解して混合し、70℃に保ち油相とする。成分1〜2及び12〜15を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分11を加え、更に30℃まで冷却して製品とする。
【0042】
比較例1 従来の乳液
実施例1において、コラーゲンペプチド(製造例4)を精製水に置き換えたものを従来の乳液とした。
【0043】
実施例8 クリーム
[製造方法]成分3〜11を加熱して混合し、70℃に保ち油相とする。成分1〜2及び13〜16を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分12を加え、更に30℃まで冷却して製品とする。
【0044】
実施例9 化粧水
[製造方法]成分1〜2、4〜7及び13と、成分3及び9〜12をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
【0045】
実施例10 軟膏
[製造方法]成分3〜7を加熱溶解して混合し、70℃に保ち油相とする。成分1〜2及8〜10を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
【0046】
実施例11 ファンデーション
[製造方法]成分3〜11を加熱溶解し、80℃に保ち油相とする。成分22に成分12をよく膨潤させ、続いて、成分1〜2及び13〜16を加えて均一に混合する。これに粉砕機で粉砕混合した成分17〜20を加え、ホモミキサーで撹拌し75℃に保ち水相とする。この水相に油相をかき混ぜながら加え、冷却し、45℃で成分21を加え、かき混ぜながら30℃まで冷却して製品とする。
【0047】
実施例12 浴用剤
[製造方法]成分1〜7を均一に混合し製品とする。
【0048】
次に、本発明の効果を詳細に説明するため、実験例を挙げる。
【0049】
実験例1 マウス皮膚におけるコラーゲン産生促進効果
6週齢のヘアレスマウスの背部皮膚に、1日1回、週5日、計3ヶ月間試料10mg/mL(2種以上の場合は総量)を含む70%エタノール溶液を10μL/cm2塗布し、最終日に皮膚をサンプリングした。皮膚コラーゲン量はヒドロキシプロリンを定量することで行った。
【0050】
結果を表1に示した。その結果、パルミチン酸レチノール単独処理またはコラーゲンペプチド単独処理に比べて、両者の併用時では明らかなコラーゲン産生量の増加が認められた。またこの効果は、コリウス熱水抽出物と併用することで、相乗的に高められた。
【0051】
【表1】
【0052】
実験例2 マウス皮膚におけるコラーゲン架橋形成阻害効果
6週齢のヘアレスマウスの背部皮膚に、紫外線B波を1日当たり100mJ/cm2、1日1回、週5日、計3ヶ月間連続で照射した。照射直後に試料10mg/mL(2種以上の場合は総量)を含む70%エタノール溶液を10μL/cm2塗布し、最終照射の翌日にコラーゲン架橋に由来する蛍光強度(励起波長360nm、蛍光波長440nm)を光ファイバー蛍光分光測定装置(SkinSkan、ホリバ社製)にて測定した。
【0053】
結果を表2に示した。その結果、パルミチン酸レチノール、コラーゲンペプチド、コリウス抽出物に優れたコラーゲン架橋形成阻害効果が認められた。またこの効果は、コラーゲンペプチドとビタミンA誘導体との併用や、コリウス熱水抽出物を組み合わせることで、相乗的に効果が高まった。
【0054】
【表2】
【0055】
実験例3 使用試験
実施例1の乳液1、実施例2の乳液2、実施例3の乳液3、実施例4の乳液4、実施例5の乳液5、実施例6の乳液6、実施例7の乳液7及び比較例1の従来の乳液を用いて、各々女性30人(30〜45才)を対象に2ヶ月間の使用試験を行った。使用後、しわ、たるみについてのアンケート調査を行って、老化防止効果を判定した。アンケートの評価基準は、有効なものを「優」、やや有効なものを「良」、わずかに有効なものを「可」、無効なものを「不可」として評価した。
【0056】
これらの結果を表3に示した。実施例1〜7に示すコラーゲンペプチド、パルミチン酸レチノール、コリウスの抽出物を含有する乳液は優れた老化防止効果を示した。なお、試験期間中皮膚トラブルは一人もなく、安全性においても問題なかった。
【0057】
【表3】
【0058】
実施例8のクリーム、実施例9の化粧水、実施例10の軟膏、実施例11のファンデーション及び実施例12の浴用剤の使用試験を行ったところ、いずれも安全で優れた老化防止効果を示した。
【0059】
【発明の効果】
以上のことから、ビタミンA誘導体、コラーゲンペプチド、コリウス抽出物を特定に組み合わせたものは、優れたコラーゲン産生促進効果及びコラーゲン架橋形成抑制効果を示した。また上記のコラーゲン産生促進剤又はコラーゲン架橋形成阻害剤を含有することを特徴とする皮膚外用剤は安全でシワの予防・改善に優れた皮膚の老化防止効果を示した。[0001]
[Technical field to which the invention belongs]
The present invention relates to a collagen production promoter and a collagen cross-linking formation inhibitor, and particularly to a collagen production promoter and a collagen cross-linking formation inhibitor that are effective in preventing and improving wrinkles, which are one of skin sensations.
[0002]
[Prior art]
Wrinkles, one of the skin changes associated with aging, are caused by a decrease in skin elasticity due to a decrease or qualitative change in collagen, which is the main component of dermal connective tissue. As a means for suppressing the formation of wrinkles, conventionally, dermal extracellular matrix components such as collagen and hyaluronic acid have been mainly applied to the skin. However, these did not have a sufficient effect.
[0003]
In recent years, vitamin A derivatives have attracted attention and are widely used as drugs for preventing / improving skin age-related changes (Patent Document 1, Non-Patent Document 1). The effects of vitamin A derivatives are extremely diverse, and one of them is known to be an effect of promoting collagen production in the skin. However, since the effect is not always satisfactory, a means for enhancing this effect has been strongly desired.
[0004]
[Patent Document 1]
JP 08-073338
[Non-Patent Document 1]
Nobuko Tsuji, Fragrance Journal, 2001, 29 (2), 37-42
[0005]
On the other hand, cross-linking is one of the qualitative changes in collagen. Collagen has a slow turnover in vivo, and cross-linking occurs within and between collagen molecules while it is present in the dermal connective tissue for a long time, resulting in a decrease in fibroblast activity and insolubilization and binding of collagen. The original physical properties of the tissue were lowered, and the elasticity of the skin was reduced (Non-Patent Documents 2, 3, and 4).
[0006]
[Non-Patent Document 2]
Mauron, Prog. Fd. Nutur. Sci. , 5: 5-35, 1981
[Non-Patent Document 3]
Howard, Exp. Cell. Res. 228: 132-137,1998.
[Non-Patent Document 4]
Tiollier, Exp. Cell. Res. , 191: 95-104, 1990.
[0007]
Accordingly, there has been a demand for a collagen crosslinking inhibitor that can prevent skin aging by inhibiting the formation of collagen crosslinks and that has no problem in terms of safety.
[0008]
It is known that a collagen peptide obtained by enzymatic degradation of collagen has an effect of promoting collagen production in fibroblasts (Patent Document 2). In addition, the extract of Coleus is known to have an effect of preventing a decrease in vitamin A receptor due to ultraviolet rays and enhancing the effect of preventing and improving wrinkles of a vitamin A derivative (Patent Document 3).
[0009]
[Patent Document 2]
JP 2000-309521 [Patent Document 3]
Japanese Patent Application No. 2003-201207 [0010]
However, it has not been reported that a collagen production effect or a collagen crosslinking formation inhibitory effect is promoted by combining a collagen peptide, a vitamin A derivative, and a Coleus extract in a specific combination.
[0011]
[Problems to be solved by the invention]
The present invention has been made under such circumstances, search for a highly safe component that promotes collagen production and inhibits cross-linking of collagen, and prevents wrinkles containing the component as an active ingredient, It is an object of the present invention to provide a collagen production promoter and a collagen crosslinking formation inhibitor that are excellent in improvement.
[0012]
[Means for Solving the Problems]
Under such circumstances, as a result of intensive studies, the present inventors have found that a collagen production promoting effect is synergistically enhanced by using a vitamin A derivative or a Coleus extract in combination with a collagen peptide. In addition, the vitamin A derivative, collagen peptide, and Coleus extract have a collagen cross-linking formation inhibitory effect, and the collagen peptide combined with the vitamin A derivative and Coleus extract synergistically enhances the collagen cross-linking formation inhibitory effect. As a result, the present invention has been completed.
[0013]
That is, the present invention is a collagen production promoter and collagen cross-linking formation inhibitor characterized by containing a vitamin A derivative, a collagen peptide, and a Coleus extract.
[0014]
Collagen or gelatin, which is a starting material for collagen peptides according to the present invention, includes bones such as cattle, pigs, birds, skin, tendons or flounder, flounder, shark, shark, shark, shark and other bones, skin, tendons, scales, A floating bag or the like can be used. The extraction or purification of the collagen or gelatin can be performed using a known method.
[0015]
The collagen peptide can be obtained by hydrolyzing the collagen peptide using a proteolytic enzyme. The enzyme to be used is not particularly limited, and trypsin, chymotrypsin, subtilisin, elastase, proline-specific protease, protease produced by Streptococcus microorganisms, protease produced by Aspergillus microorganisms, Streptomyces microorganisms produced Proteases produced by microorganisms belonging to the genus Rhizopus, proteases produced by microorganisms belonging to the genus Bacillus, proteases produced by lactic acid bacteria, papain, bromelain, kukumycin, pepsin, thermolysin and the like. Collagenases derived from bacteria such as Clostridium genus and Streptomyces genus, actinomycetes or fungi can also be used. Further, it may be a protease produced in another microbial cell by a genetic recombination technique. Further, a plurality of enzymes may be mixed and used.
[0016]
The amount of the enzyme used for hydrolysis is about 0.01% to 10%, preferably about 0.1 to 5% by weight with respect to the raw material, and the temperature condition is room temperature to 90 ° C., preferably 37 ° C. to 55%. The reaction time is 1 to 24 hours, preferably 1 to 8 hours. The pH condition is adjusted to the optimum pH before adding the enzyme. After completion of hydrolysis, the enzyme is deactivated by heating, and after cooling, filtration, decolorization, deodorization, desalting, concentration, and drying are performed as necessary.
[0017]
The collagen peptide of the present invention can be obtained by adjusting reaction conditions such as enzyme type, concentration, and reaction time. The average molecular weight of the collagen peptide is preferably 280 to 3000, particularly preferably 500 to 1500. As the hydrolyzate by an enzyme, a fraction having a specific molecular weight can be obtained by using a known method such as gel filtration chromatography.
[0018]
The Labiatae plant used in the present invention belongs to the genus Solenostemon, Coleus, etc., and includes Solenostemon scutellarioides, Coleus blumei, and Coleus scutellarioides. And Coleus labiatae. In particular, Solenostemon scutellarioides and Coleus bulmay are widely sold as garden varieties "Coleus". Of these, Coleus scutellarioides, which is said to be a colored leaf grass in China, is preferable.
[0019]
The plant extract belonging to the specific Lamiaceae used in the present invention is extracted from a part of the plant body such as leaves, stems, flowers, roots or the whole plant. Preferably, those extracted from the leaves and stems of the plant body are good. The extraction method is not particularly limited, and for example, it may be a heat extraction or a room temperature extraction.
[0020]
Examples of the solvent to be extracted include water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1,3-butylene glycol, propylene glycol). , Glycerin, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran, propyl ether) Etc.). Preferred are polar solvents such as water, lower alcohols and liquid polyhydric alcohols, and particularly preferred are water, ethanol, 1,3-butylene glycol and propylene glycol. These solvents may be used alone or in combination of two or more.
[0021]
The extract may be used as it is, or may be used after concentration, dilution and filtration treatment, decolorization with activated carbon, deodorization treatment, or the like, if necessary. Further, the extracted solution may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product.
[0022]
The vitamin A derivatives used in the present invention are retinol acetate, retinol palmitate, vitamin A oil, etc., and commercially available products can be used.
[0023]
As the collagen production promoter and collagen cross-linking formation inhibitor of the present invention, the above-mentioned vitamin A derivative, collagen peptide and Coleus extract may be used as they are. Fats and oils, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, metal soaps, pH adjusters, preservatives, fragrances, moisturizers, powders, ultraviolet absorbers, which are components used Components such as thickeners, pigments, antioxidants, whitening agents, chelating agents, excipients, stabilizers, preservatives, binders, and disintegrants can also be blended.
[0024]
The collagen production promoter and collagen cross-linking formation inhibitor used in the present invention can be used in any of cosmetics, quasi-drugs, and pharmaceuticals. Examples of the dosage form include skin lotions, creams, emulsions, and gels. , Aerosol agents, ointments, poultices, paste agents, plaster agents, essences, packs, cleaning agents, bath preparations, foundations, powders, lipsticks, and the like.
[0025]
The compounding amount of the vitamin A derivative, collagen peptide, and Coleus extract used in the present invention is not particularly limited, but the total amount of the collagen production accelerator, collagen cross-linking inhibitor, and external preparation for skin of the present invention is converted to a dry product. The range is preferably 0.0001 to 75% by weight, and more preferably 0.001 to 30% by weight. If it is 0.0001% by weight or less, the effect of promoting collagen production and the effect of suppressing the formation of collagen crosslinks are low. The addition method may be added in advance or during the production, and may be appropriately selected in consideration of workability.
[0026]
Next, in order to describe the present invention in detail, examples of production of the extract used in the present invention, formulation examples and experimental examples will be given as examples, but the present invention is not limited thereto. The compounding amount shown in the examples indicates% by weight.
[0027]
Production Example 1 Collagen peptide 1 by papain hydrolysis
As collagen protein, 30 g of gelatin prepared from scab was dissolved by heating in 300 mL of distilled water. Papain (manufactured by Amano Enzyme) (300 mg) was added, the pH was adjusted to 7.0 with aqueous ammonia, and the mixture was allowed to stand at 50 ° C. for 1 hour. After completion of the reaction, the reaction solution was heated at 100 ° C. for 15 minutes to deactivate the enzyme. Next, after treatment with activated carbon, freeze-drying was performed to obtain a collagen peptide having an average molecular weight of 3000.
[0028]
Production Example 2 Collagen peptide 2 by papain hydrolysis
Gel filtration chromatography using Bio-Gel P-2 (manufactured by BIO-RAD) in which the activated carbon treatment solution in Production Example 1 was equilibrated with distilled water was performed, and fractions having an average molecular weight of 2000, 800, and 280 were lyophilized. did.
[0029]
Production Example 3 As a collagen peptide collagen protein by collagenase hydrolysis, 30 g of gelatin prepared from scales was dissolved by heating in 300 mL of distilled water. 300 mg of collagenase type I (manufactured by Worthington Biochemical Corp) was added, the pH was adjusted to 7.5 with aqueous ammonia, and the mixture was allowed to stand at 37 ° C. for 1 hour. After completion of the reaction, the reaction solution was heated at 100 ° C. for 15 minutes to deactivate the enzyme. Next, after treatment with activated carbon, freeze drying was performed to obtain a collagen peptide having an average molecular weight of 400.
[0030]
Production Example 4 Collagen peptide 1 produced by protease hydrolysis produced by Papain and Bacillus microorganisms
As collagen protein, 30 g of gelatin prepared from flounder skin was dissolved by heating in 300 mL of distilled water. 300 mg each of papain (manufactured by Amano Enzyme) and protease produced by a microorganism belonging to the genus Bacillus (manufactured by Amano Enzyme) were added, adjusted to pH 7.5 with aqueous ammonia, and allowed to stand at 50 ° C. for 3 hours. After completion of the reaction, the reaction solution was heated at 100 ° C. for 15 minutes to deactivate the enzyme. Next, after the activated carbon treatment, freeze-dried collagen peptide having an average molecular weight of 1500 was obtained.
[0031]
Production Example 5 Collagen Peptide 2 Protease Hydrolyzed Produced by Papain and Bacillus Microorganisms 2
Gel filtration chromatography using Bio-Gel P-2 (manufactured by BIO-RAD) in which the activated carbon treatment solution of Production Example 4 was equilibrated with distilled water was performed, and a fraction having an average molecular weight of 800 was freeze-dried.
[0032]
Production Example 6 Coleus hot water extract 400 g of purified water was added to 20 g of the dried plant of Coleus scutellarioides, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated and lyophilized. As a result, 1.8 g of hot water extract of Coleus was obtained.
[0033]
Production Example 7 Coleus ethanol extract 100 g of ethanol was added to 100 g of dried plant of Coleus (Cutella rioides), extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain an ethanol extract of Coleus. 5.9g was obtained.
[0034]
Production Example 8 Coleus 50% 1,3-butylene glycol extract 1 kg of purified water and 1 kg of 1,3-butylene glycol were added to 100 g of a dried product of the whole plant of Coleus (Coleus scutellarioides), and extracted at room temperature for 7 days. Filtration gave 1.9 kg of 50% 1,3-butylene glycol extract of Coleus.
[0035]
Example 1 Latex 1
[Production Method] Components 2 to 8 are heated and dissolved and mixed, and the mixture is kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 10-13 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
[0036]
Example 2 Latex 2
[Manufacturing method] Components 1 to 8 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 10 to 13 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
[0037]
Example 3 Latex 3
[Production Method] Components 2 to 8 are heated and dissolved and mixed, and the mixture is kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 10-13 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
[0038]
Example 4 Latex 4
[Manufacturing method] Components 2 to 9 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 11 to 14 are heated and dissolved and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
[0039]
Example 5 Latex 5
[Manufacturing method] Components 2 to 9 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 11 to 14 are heated and dissolved and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
[0040]
Example 6 Latex 6
[Manufacturing method] Components 3 to 9 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1-2 and 11-14 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
[0041]
Example 7 Latex 7
[Manufacturing method] Components 3 to 10 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1-2 and 12-15 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 11 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
[0042]
Comparative Example 1 Conventional Emulsion In Example 1, the collagen peptide (Production Example 4) was replaced with purified water to obtain a conventional emulsion.
[0043]
Example 8 Cream
[Manufacturing method] Components 3 to 11 are heated and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1-2 and 13-16 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
[0044]
Example 9 Lotion
[Production method] Components 1-2, 4-7 and 13 and components 3 and 9-12 are dissolved uniformly, and both are mixed and filtered to obtain a product.
[0045]
Example 10 Ointment
[Manufacturing method] Components 3 to 7 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1-2, 8-10 are heated and dissolved and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled to 30 ° C. with stirring to obtain a product.
[0046]
Example 11 Foundation
[Production Method] Components 3 to 11 are heated and dissolved, and kept at 80 ° C. to obtain an oil phase. Ingredient 22 is well swollen with ingredient 12, and then ingredients 1-2 and 13-16 are added and mixed uniformly. To this, components 17 to 20 pulverized and mixed with a pulverizer are added, and the mixture is stirred with a homomixer and kept at 75 ° C. to obtain an aqueous phase. The oil phase is added to this aqueous phase with stirring, cooled, component 21 is added at 45 ° C., and cooled to 30 ° C. with stirring to give a product.
[0047]
Example 12 Bath agent
[Production Method] Components 1 to 7 are uniformly mixed to obtain a product.
[0048]
Next, experimental examples will be given to explain the effects of the present invention in detail.
[0049]
Experimental Example 1 Collagen production promoting effect in mouse skin The back skin of a 6-week-old hairless mouse contains 10 mg / mL (total amount in the case of two or more) of 10 mg / mL once a day, 5 days a week for a total of 3 months. % Ethanol solution was applied at 10 μL / cm 2 and the skin was sampled on the last day. The amount of skin collagen was determined by quantifying hydroxyproline.
[0050]
The results are shown in Table 1. As a result, compared with retinol palmitate alone treatment or collagen peptide alone treatment, an apparent increase in collagen production was observed when both were used in combination. This effect was also synergistically enhanced when used in combination with the Coleus hot water extract.
[0051]
[Table 1]
[0052]
Experimental Example 2 Collagen Crosslink Formation Inhibitory Effect on Mouse Skin Ultraviolet B wave was irradiated to the back skin of a 6-week-old hairless mouse at 100 mJ / cm 2 per day, once a day, 5 days a week for a total of 3 months. . Immediately after the irradiation, 10 μL / cm 2 of a 70% ethanol solution containing 10 mg / mL (total amount in the case of two or more samples) was applied, and the fluorescence intensity derived from collagen cross-linking on the next day after the final irradiation (excitation wavelength 360 nm, fluorescence wavelength 440 nm). ) Was measured with an optical fiber fluorescence spectrometer (SkinScan, manufactured by Horiba).
[0053]
The results are shown in Table 2. As a result, an excellent collagen cross-linking formation inhibitory effect was observed in retinol palmitate, collagen peptide, and Coleus extract. In addition, this effect was synergistically enhanced by using a combination of a collagen peptide and a vitamin A derivative or a Coleus hot water extract.
[0054]
[Table 2]
[0055]
Experimental Example 3 Usage Test Emulsion 1 of Example 1, Emulsion 2 of Example 2, Emulsion 3 of Example 3, Emulsion 4 of Example 4, Emulsion 5 of Example 5, Emulsion 6 of Example 6, Example 7 No. 7 and the conventional emulsion of Comparative Example 1 were used, and a use test for 2 months was conducted on 30 women (30 to 45 years old). After use, a questionnaire survey on wrinkles and sagging was conducted to determine the anti-aging effect. The evaluation criteria of the questionnaire were evaluated as “excellent” for valid, “good” for slightly effective, “good” for slightly effective, and “impossible” for invalid.
[0056]
These results are shown in Table 3. The emulsion containing the collagen peptide, retinol palmitate, and Coleus extract shown in Examples 1 to 7 showed an excellent anti-aging effect. During the test period, there was no skin problem and there was no problem with safety.
[0057]
[Table 3]
[0058]
When the usage test of the cream of Example 8, the lotion of Example 9, the ointment of Example 10, the foundation of Example 11 and the bath preparation of Example 12 was conducted, all showed a safe and excellent anti-aging effect. It was.
[0059]
【The invention's effect】
From the above, a specific combination of vitamin A derivative, collagen peptide and Coleus extract showed excellent collagen production promoting effect and collagen cross-linking formation inhibiting effect. Moreover, the skin external preparation characterized by containing said collagen production promoter or collagen cross-linking formation inhibitor showed a safe and anti-aging effect on skin that was excellent in preventing and improving wrinkles.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003205800A JP4436084B2 (en) | 2003-08-04 | 2003-08-04 | Collagen production promoter and collagen cross-linking formation inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003205800A JP4436084B2 (en) | 2003-08-04 | 2003-08-04 | Collagen production promoter and collagen cross-linking formation inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005053797A JP2005053797A (en) | 2005-03-03 |
| JP4436084B2 true JP4436084B2 (en) | 2010-03-24 |
Family
ID=34362913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003205800A Expired - Lifetime JP4436084B2 (en) | 2003-08-04 | 2003-08-04 | Collagen production promoter and collagen cross-linking formation inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4436084B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005053798A (en) * | 2003-08-04 | 2005-03-03 | Nonogawa Shoji Kk | Fibronectin production promoter |
| JP4904021B2 (en) * | 2005-06-09 | 2012-03-28 | 新田ゼラチン株式会社 | Collagen peptide-containing cosmetic composition and method for producing the same |
| FR2900155B1 (en) * | 2006-04-21 | 2008-06-27 | Diana Naturals Sa | AVIAN CARTILAGE HYDROLISATE, PROCESS FOR OBTAINING AND USES |
| JP5689222B2 (en) * | 2006-11-15 | 2015-03-25 | 株式会社明治 | Collagen peptide composition and food and drink containing the same |
| JP6608109B2 (en) * | 2016-03-23 | 2019-11-20 | 富士フイルム株式会社 | Method for enhancing the expression of Endo180 in dermal fibroblasts |
| CN119592649A (en) * | 2024-12-09 | 2025-03-11 | 中科华诺(广东)医药生物科技有限公司 | Small molecule protein peptide for enhancing transdermal absorption and application thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3118020B2 (en) * | 1991-05-13 | 2000-12-18 | 有限会社野々川商事 | Cosmetics |
| JPH0873338A (en) * | 1994-09-02 | 1996-03-19 | Noevir Co Ltd | Skin external preparation |
| JPH10291929A (en) * | 1997-04-21 | 1998-11-04 | Nagase & Co Ltd | Wrinkle suppressive preparation for external use for skin |
| JP3504205B2 (en) * | 1999-02-23 | 2004-03-08 | 株式会社資生堂 | External preparation for skin |
| JP2001342489A (en) * | 2000-03-31 | 2001-12-14 | Sanei Gen Ffi Inc | Agent for suppressing deterioration of taste and flavor and method for suppressing deterioration of taste and flavor |
| JP2003095913A (en) * | 2001-09-21 | 2003-04-03 | Ichimaru Pharcos Co Ltd | Cosmetic composition or food and drink |
| JP2003137807A (en) * | 2001-11-01 | 2003-05-14 | Miyagi Kagaku Kogyo Kk | Collagen production promoter, cosmetics, food and medicine containing the same, and external preparation for prevention or improvement of skin diseases |
| JP3581125B2 (en) * | 2001-12-03 | 2004-10-27 | 有限会社野々川商事 | Anti-aging cosmetics |
| JP2003192567A (en) * | 2001-12-27 | 2003-07-09 | Nonogawa Shoji Kk | Cosmetic |
| JP4485154B2 (en) * | 2003-07-24 | 2010-06-16 | 日本メナード化粧品株式会社 | Skin external preparation for wrinkle prevention improvement |
-
2003
- 2003-08-04 JP JP2003205800A patent/JP4436084B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005053797A (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8674072B2 (en) | Cosmetic and/or pharmaceutical composition comprising a peptidic hydrolyzate that can reinforce the barrier function | |
| CN102762189B (en) | Cosmetic and/or pharmaceutical composition comprising an extract of carob as active agent for activating aquaporin expression | |
| KR102033837B1 (en) | Aqueous extract of truffle and cosmetic composition thereof | |
| JP4436084B2 (en) | Collagen production promoter and collagen cross-linking formation inhibitor | |
| KR20200041667A (en) | A composition for improving a skin and a method of preparing the composition | |
| KR20200016813A (en) | Composition for skin whitening comprising enzymatic hydrolysates of insect | |
| JP2003095858A (en) | Skin care preparation | |
| WO2007081190A1 (en) | Novel use of 1,2,3,4,6-penta-o-galloyl-beta-d-glucose | |
| JP4460420B2 (en) | Collagen production promoter | |
| JP2004099503A (en) | Hgf production promoter and cosmetic containing the same | |
| FR2971711A1 (en) | Use of extract of Einkorn wheat (Triticum monococcum), as active agent for activating synthesis of extracellular matrix protein of skin, in cosmetic composition comprising medium for fighting against the appearance of signs of skin aging | |
| KR20220072487A (en) | Composition for skin external application comprising ponciri fructus glycoprotein hydrolysate for strengthening skin barrier function and alleviating skin stress | |
| KR102214505B1 (en) | Skin External Preparation and Cosmetic Compositions Comprising Extract of Viburnum erosum Thunb. | |
| WO2007003771A2 (en) | Use of a yeast extract in the form of an active agent for inducing a synthesis of sirt proteins in skin cells | |
| JP2005053798A (en) | Fibronectin production promoter | |
| KR20190047582A (en) | Two Step-sequential Enzyme treated extract of Plant originated materials, its functional cosmetic composition comprising the same and method producing the same | |
| KR102041958B1 (en) | Composition for skin-whitening containing mixed extracts as a active ingredients, and manufacturing method for composition and cosmetic composition | |
| JP5926507B2 (en) | Method for producing matrix metalloprotease inhibitor, method for producing elastase inhibitor, method for producing hyaluronidase inhibitor, and method for producing a skin external preparation for preventing wrinkles | |
| JP2003192565A (en) | Cosmetic | |
| KR20180088173A (en) | A cosmetic composition comprising extracts of cladosiphon novae - caledoniae kylin | |
| JP2004203777A (en) | Anti-aging cosmetics | |
| KR20080069816A (en) | Composition for improving skin wrinkles and elasticity | |
| JP2007039394A (en) | External preparation for skin for preventing and ameliorating aging | |
| KR102891649B1 (en) | Method for preparing extract of fermented golden silk for antioxidant, anti-wrinkle and skin cell regeneration and cosmetic composition containing extract of fermented golden silk | |
| JP2004051580A (en) | Anti-aging agent, Maillard reaction inhibitor, collagenase activity inhibitor, and cosmetic for preventing skin aging containing these |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060620 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090721 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090917 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091020 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091222 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091225 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4436084 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130108 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140108 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |